GeneCraft
GeneCraft is a pre-clinical-stage South Korean biotech developing gene therapy for K-RAS mutated cancers. Its lead program RX001, a first-in-class Pan K-RAS lung cancer treatment, leverages the proprietary Ubi-AAV Platform to selectively induce cancer cell death while sparing normal cells.
- Company typePrivate
- Founded2020
- HeadquartersSeongnam, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What GeneCraft does
GeneCraft is a pre-clinical-stage biotechnology company developing gene therapies for cancers driven by K-RAS mutations. Headquartered in Cheongju-si with an R&D center in Seoul, South Korea, the company targets Pan K-RAS mutated cancers—an indication class historically considered undruggable by conventional small-molecule and antibody approaches. The scientific program is grounded in 30+ years of academic research by Co-Founder and Co-CEO Prof. Suk Chul Bae on the RUNX3 tumor suppressor and its role as a pioneer factor regulating the innate oncogene defense system. The company employs 11–50 people and operates as a privately held, founder-led entity.
GeneCraft's core technology is the proprietary Ubi-AAV Platform, which enables crafting of gene contents into new AAV-based gene therapeutics. Its lead program, RX001, is positioned as a first-in-class treatment for Pan K-RAS mutated lung cancer. RX001 is designed to distinguish abnormal K-RAS mutated cancer cells from normal cells and selectively induce cancer cell death by orchestrating the innate oncogene defense system, with claimed selectivity that spares healthy tissue. Supporting scientific evidence is anchored in peer-reviewed publications in Cell, Nature Communications, and Oncogene covering RUNX3 biology, K-RAS evasion mechanisms, and restriction-point defense against cellular transformation. Manufacturing capability is supported through a strategic partnership with GenScript Probio, signed via MOU in November 2022, for AAV gene therapy development and production.
GeneCraft is pre-revenue with no commercialized products and no current product sales. Its business model is structured around eventual monetization through out-licensing, co-development agreements, and strategic alliances with pharmaceutical partners. The company has raised approximately $8.3 million across disclosed funding rounds, including a 2024 Series 2 round led by Cosine Investment, InfoBank, and the Seoul National University SNU R&DB Foundation, plus a 2025 investment from Korea Venture Investment Corp and additional new-share issuances in 2023. The prospective end-customer population is K-RAS mutated cancer patients—particularly those with lung adenocarcinoma—who have exhausted standard-of-care options; near-term counterparties are pharmaceutical companies and clinical collaborators evaluating in-licensing or co-development of the pipeline.
GeneCraft firmographics
Firmographics- Name
- GeneCraft
- Legal name
- GeneCraft
- Website
- https://genecraft.co.kr
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GeneCraft is a pre-clinical-stage South Korean biotech developing gene therapy for K-RAS mutated cancers. Its lead program RX001, a first-in-class Pan K-RAS lung cancer treatment, leverages the proprietary Ubi-AAV Platform to selectively induce cancer cell death while sparing normal cells.
- Ownership category
- akta.pro rank
GeneCraft industry classification
Industry- Product category
- Oncology Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where GeneCraft is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
GeneCraft business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Future Pharmaceutical/Gene Therapy Pipeline: Pre-clinical stage biotech company developing gene therapy candidates for cancer treatment. No current revenue; future revenue expected through pharmaceutical licensing, co-development partnerships, or eventual product commercialization upon successful clinical development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
GeneCraft product offering
Product offeringCore offering
GeneCraft develops gene therapy drug candidates for K-RAS mutated cancers using its proprietary Ubi-AAV Platform. The lead candidate RX001 is designed to selectively induce death of Pan K-RAS mutated cancer cells while sparing normal cells, building on 30+ years of RUNX3 research. The company is pre-clinical and pursues clinical collaboration, strategic alliances, and licensing partnerships with pharmaceutical companies to advance and eventually commercialize its pipeline.
Product overview
GeneCraft is a pre-clinical-stage biotech company developing a gene therapy pipeline focused on oncology. The company operates with two core offerings: RX001, a first-in-class gene therapy drug candidate for Pan K-RAS mutated lung cancer that selectively targets and induces death of cancer cells while sparing normal cells, and the Ubi-AAV Platform, a proprietary technology that enables the crafting of gene contents into new AAV-based gene therapeutics. The pipeline is designed to unlock next-level oncology treatment by building on advances in gene therapy to transform treatment paradigms for K-RAS mutated cancers.
Differentiator
Problem solved
Functional benefit
Brands
- RX001: First-in-class treatment for Pan K-RAS mutated lung cancer using Ubi-AAV Platform technology
- Ubi-AAV Platform
Products and services
- RX001 RX001 is a first-in-class gene therapy drug candidate designed for Pan K-RAS mutated lung cancer. It distinguishes abnormal K-RAS mutated cancer cells from normal cells and selectively induces death of the cancer cells by orchestrating a gene-driven, innate oncogene defense system. The candidate is currently in pre-clinical development and intended for pharmaceutical licensing or co-development partnerships.
- Ubi-AAV Platform Ubi-AAV Platform is GeneCraft's proprietary AAV gene therapy platform technology that enables the crafting of gene contents into new gene therapeutics for treating cancer patients with K-RAS mutations. It is leveraged internally to build the RX001 program and is part of the company's external partnership and licensing offering.
Quantifiable outcome
- Selective targeting of K-RAS mutated cancer cells while sparing normal cells
Companies that use GeneCraft
Customer profileSegments1 record
Ideal customer profiles3 records
GeneCraft technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
GeneCraft partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GenScript ProbiocoreGeneCraft signed an MOU with GenScript Probio to form a strategic partnership for the development and production of new AAV (Adeno-Associated Virus) gene therapies. This partnership leverages GenScript Probio's expertise in biologics development and manufacturing to advance GeneCraft's gene therapy pipeline.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
GeneCraft competitors and assessment
Company assessmentDirect peers
- Verve Therapeutics: Clinical-stage US biotech developing in vivo AAV-based gene therapies (base editing and gene replacement) for serious diseases. Highly comparable to GeneCraft as both pursue in vivo AAV gene therapy with platform-level ambitions to address historically hard-to-drug targets.
- uniQure: Clinical-stage gene therapy company specializing in AAV-based therapeutics with multiple programs in CNS and other indications. Comparable to GeneCraft as a focused AAV gene therapy developer pursuing platform-based pipeline expansion.
- Regenxbio: Clinical-stage AAV gene therapy company with proprietary NAV technology platform for licensing to other gene therapy developers. Directly comparable to GeneCraft's Ubi-AAV Platform approach of providing enabling AAV technology for therapeutic development.
Emerging players
- Beam Therapeutics: Clinical-stage biotech developing base editing therapies including programs targeting K-RAS mutations in cancer. Comparable to GeneCraft as both pursue next-generation genetic medicine approaches to address K-RAS-driven cancers.
- Revolution Medicines: Clinical-stage oncology biotech developing pan-RAS and K-RAS-specific inhibitors including RMC-6236. Comparable to GeneCraft as a competing approach to targeting K-RAS-driven cancers, though via small molecule rather than gene therapy.
- Adicet Bio: Clinical-stage biotech developing engineered gamma-delta T cell therapies for oncology. Comparable to GeneCraft as a cell/gene therapy developer pursuing novel mechanisms to treat cancer patients with limited options.
Broad incumbents
- Intellia Therapeutics: Clinical-stage biotech developing in vivo CRISPR/Cas9 gene editing therapies with AAV and LNP delivery. Comparable to GeneCraft as a developer of in vivo genetic medicines for serious diseases using viral and non-viral delivery platforms.
- Mirati Therapeutics: Acquired by BMS, developer of Krazati (adagrasib), an FDA-approved K-RAS G12C inhibitor. Comparable to GeneCraft as a competing K-RAS oncology player pursuing durable responses in K-RAS-mutated cancers.
- CRISPR Therapeutics: Clinical-stage gene editing biotech with approved Casgevy therapy and oncology pipeline. Comparable to GeneCraft as a developer of genetic medicines for serious diseases including oncology.
Others
- GenScript Probio: CDMO specializing in viral vector and biologics manufacturing, partnered with GeneCraft for AAV development. Comparable to GeneCraft as an ecosystem participant providing manufacturing infrastructure critical to AAV gene therapy development.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
GeneCraft social profiles
Digital presenceGeneCraft financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneCraft leadership team
Management profileNumber of profiles
Profiles2 records
GeneCraft funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneCraft M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneCraft
What does GeneCraft do?
GeneCraft develops gene therapy drug candidates for K-RAS mutated cancers using its proprietary Ubi-AAV Platform. The lead candidate RX001 is designed to selectively induce death of Pan K-RAS mutated cancer cells while sparing normal cells, building on 30+ years of RUNX3 research. The company is pre-clinical and pursues clinical collaboration, strategic alliances, and licensing partnerships with pharmaceutical companies to advance and eventually commercialize its pipeline.
Is GeneCraft a public or private company?
GeneCraft is a private company. It is classified as venture growth investor backed and is currently operating.
When was GeneCraft founded?
GeneCraft was founded in 2020. It employs 11 to 50 people.
Where is GeneCraft based?
GeneCraft is headquartered in Seongnam, South Korea, in the Asia region.
How does GeneCraft make money?
One revenue line is on record: future Pharmaceutical/Gene Therapy Pipeline.
Who are GeneCraft's main competitors?
Direct peers on record are Verve Therapeutics, uniQure and Regenxbio. Emerging players are Beam Therapeutics, Revolution Medicines and Adicet Bio. Broad incumbents are Intellia Therapeutics, Mirati Therapeutics and CRISPR Therapeutics. GenScript Probio is listed as an others.
Does GeneCraft have an API?
No public API is recorded for GeneCraft.
What industry is GeneCraft in?
GeneCraft's product category is Oncology Gene Therapy. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.